CIARCIELLO v. BIOVENTUS INC.

CourtDistrict Court, M.D. North Carolina
DecidedDecember 18, 2024
Docket1:23-cv-00032
StatusUnknown

This text of CIARCIELLO v. BIOVENTUS INC. (CIARCIELLO v. BIOVENTUS INC.) is published on Counsel Stack Legal Research, covering District Court, M.D. North Carolina primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
CIARCIELLO v. BIOVENTUS INC., (M.D.N.C. 2024).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF NORTH CAROLINA ROBERT CIARCIELLO Individually ) and on Behalf of All Others Similarly ) Situated, ) ) Plaintiff, ) ) v. ) 1:23-CV-32 ) BIOVENTUS INC., KENNETH M. ) REALI, MARK SINGLETON, ) GREGORY ANGLUM, and SUSAN ) STALNECKER, ) ) Defendants. ) MEMORANDUM OPINION AND ORDER Catherine C. Eagles, Chief District Judge. This is a securities class action involving allegations that the defendants made false or misleading statements about securities offered by Bioventus, Inc. In August 2024, the Court preliminarily approved a proposed settlement agreement, ordered settlement notices to be sent to the putative class members, and set a date for a final settlement fairness hearing. The plaintiffs have now moved for final approval of the settlement terms under Federal Rule of Civil Procedure 23, approval of the plan of allocation, and for attorneys’ fees and other disbursements. The final settlement hearing was held on December 13, 2024. In light of its experience, the Court has considered the record, including, inter alia, the lack of objections by any class members, the proposed settlement agreement, the supporting documents, and the statements of counsel during the final settlement hearing and previous hearings. The Court finds that the proposed settlement meets the requirements of Rule 23 and that the plan of allocation and requested attorneys’ fees and other disbursements are fair and reasonable.

I. Background Bioventus is a medical device and pharmaceutical company. See Doc. 58 at ¶¶ 2, 39–40; Doc. 81 at ¶¶ 2, 39–40. In February 2021, it issued 9.2 million shares of Class A common stock in its initial public offering. Doc. 58 at ¶ 77; Doc. 81 at ¶ 77. Between February 2021 and November 2022, the defendants made statements in

SEC filings and other public disclosures about Bioventus’ projected revenue, financial performance, revenue recognition, and internal controls. See, e.g., Doc. 58 at ¶¶ 76, 78– 79, 103; Doc. 81 at ¶¶ 76, 78–79, 103. After multiple allegedly corrective disclosures in November 2022, Bioventus’ stock price declined significantly. Doc. 58 at ¶¶ 23–26. In January 2023, Robert Ciarciello, a former Bioventus shareholder, see Doc. 1 at

33, filed a class action complaint against Bioventus and the named company executives, alleging Defendants made false and misleading statements that caused Bioventus’ stock price to be overinflated.1 See generally id. According to the plaintiff, the overinflation and the drop in stock price that followed the corrective disclosures caused shareholders to suffer financial injury. See id. at ¶¶ 40–83.

1 The defendants Kenneth Reali, Mark Singleton, Gregory Anglum, and Susan Stalnecker hold or held various leadership positions at Bioventus during the relevant period. See Doc. 58 at ¶¶ 34–37; Doc. 81 at ¶¶ 34–37. This order collectively refers to Bioventus and the named defendants as Defendants; the parties do the same in their amended Stipulation of Settlement. See Doc. 148-1 at ¶ 1.4. Other shareholders expressed interest in serving as lead plaintiff under the Securities Act of 1933 (“Securities Act”) and the Securities Exchange Act of 1934 (“Exchange Act”) as amended by the Private Securities Litigation Reform Act of 1995

(“PSLRA”).2 Doc. 7; Doc. 11; Doc. 16; Doc. 19. In April 2023, the Court appointed Wayne County Employees’ Retirement System (“Wayne”) as lead plaintiff and Bleichmar Fonti & Auld LLP in association with Tin Fulton Walker & Owen PLLC as lead counsel. Doc. 44. Wayne filed an amended complaint in July 2023, asserting two violations of the

Securities Act and two violations of the Exchange Act. Doc. 58. In general, Wayne contended that Defendants were aware they were using faulty assumptions to calculate rebates Bioventus was likely to owe in the future, Defendants knew that Bioventus’ financial projections were based on untrustworthy numbers, Defendants failed to improve the rebate estimation process, and Defendants continued to report revenue based on the

inadequate estimation process. See Doc. 75 at 1–4 (summarizing allegations in operative complaint). The Court dismissed the Securities Act claims in November 2023 on Rule 12(b)(6) grounds but allowed the Exchange Act claims to proceed. Id. at 11–12. In those two remaining claims, Wayne alleges Defendants violated § 10(b) of the Exchange Act, as

implemented by SEC Rule 10b-5, and § 20(a) of the Exchange Act. Doc. 58 at ¶¶ 339– 344; see also Doc. 75 at 12.

2 See 15 U.S.C. § 77z-1(a)(3)(B)(i); 15 U.S.C. § 78u-4(a)(3)(B)(i). In March 2024, Wayne asked the Court to certify the proposed class and to appoint Wayne as class representative, Bleichmar as class counsel, and Tin Fulton as local class counsel. Doc. 89. Defendants opposed class certification. Doc. 111.

While that motion was pending, the parties met with mediator Jed Melnick and reached a conditional settlement agreement. Doc. 136. On July 15, 2024, Wayne filed an unopposed motion for preliminary approval of class action settlement, Doc. 137, a signed Stipulation of Settlement, Doc. 137-1, and copies of the proposed notices and claim form. Docs. 137-3, 137-4, 137-5, 137-6. For purposes of settlement only, the parties stipulated

and agreed to (a) the certification of the litigation as a class action on behalf of the settlement class; (b) the certification of the plaintiff as class representative; and (c) appointment of lead counsel as class counsel. Doc. 137-1 at ¶ 9.3. On August 7, 2024, the Court held a hearing on preliminary approval of the settlement. Minute Entry 08/07/2024. In response to some of the Court’s questions, the

parties filed amended versions of the Stipulation of Settlement, Doc. 148-1, the long- form notice, Doc. 148-2, and the claim form. Doc. 148-3. On August 13, 2024, the Court granted preliminary approval of the amended Stipulation, Doc. 150 at ¶ 1; preliminarily certified the class, Wayne as class representative, and Wayne’s counsel as class counsel, id. at ¶ 5; approved the proposed notices and claim form, id. at ¶ 7;

appointed A.B. Data Ltd. as Claims Administrator, id. at ¶ 8; and set a final settlement hearing. Id. at ¶ 4. On November 8, 2024, Wayne filed an unopposed motion for final approval of the class action settlement as set forth in Doc. 148-1 and the plan of allocation as set forth in Doc. 148-2 at 29–37, Doc. 163, and a motion for attorneys’ fees, expenses, and a service award. Doc. 165. Wayne also filed supporting briefs, Docs. 164, 166, and a declaration by Wayne’s counsel with exhibits. Doc. 167. These filings included a declaration by a

project manager at A.B. Data Ltd. attesting to its compliance with the notice plan approved by the Court and stating the number of opt-outs, objections, and claims submitted to date. Doc. 167-5. On December 6, 2024, Wayne filed a supplemental brief and declaration stating the updated number of opt-outs, objections, and claims submitted to date. Docs. 168, 169.

The Court held a final settlement hearing on December 13, 2024. Minute Entry 12/13/2024. Wayne’s counsel confirmed that no objections had been filed, reviewed the status of the claims process, and summarized the reasons the motions should be granted. The defendants were present through counsel and did not object to either motion. II. Certification of Settlement Classes

“The class action is an exception to the usual rule that litigation is conducted by and on behalf of the individual named parties only.” Comcast Corp. v. Behrend, 569 U.S. 27, 33 (2013) (cleaned up).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Boeing Co. v. Van Gemert
444 U.S. 472 (Supreme Court, 1980)
Blum v. Stenson
465 U.S. 886 (Supreme Court, 1984)
Basic Inc. v. Levinson
485 U.S. 224 (Supreme Court, 1988)
Blanchard v. Bergeron
489 U.S. 87 (Supreme Court, 1989)
Amchem Products, Inc. v. Windsor
521 U.S. 591 (Supreme Court, 1997)
In Re Abrams & Abrams, Pa
605 F.3d 238 (Fourth Circuit, 2010)
Erica P. John Fund, Inc. v. Halliburton Co.
131 S. Ct. 2179 (Supreme Court, 2011)
Wal-Mart Stores, Inc. v. Dukes
131 S. Ct. 2541 (Supreme Court, 2011)
In Re Jiffy Lube Securities Litigation
927 F.2d 155 (Fourth Circuit, 1991)
Nachshin v. Aol, LLC
663 F.3d 1034 (Ninth Circuit, 2011)
In Re: Painewebber Limited Partnerships Litigation
147 F.3d 132 (Second Circuit, 1998)
Comcast Corp. v. Behrend
133 S. Ct. 1426 (Supreme Court, 2013)
Grissom v. the Mills Corp.
549 F.3d 313 (Fourth Circuit, 2008)
Ward v. Dixie National Life Insurance Company
595 F.3d 164 (Fourth Circuit, 2010)
Jones v. Dominion Resources Services, Inc.
601 F. Supp. 2d 756 (S.D. West Virginia, 2009)
Domonoske v. Bank of America, N.A.
790 F. Supp. 2d 466 (W.D. Virginia, 2011)
In Re Microstrategy, Inc. Securities Litigation
172 F. Supp. 2d 778 (E.D. Virginia, 2001)
Kay Co. v. Equitable Production Co.
749 F. Supp. 2d 455 (S.D. West Virginia, 2010)
EQT Production Company v. Robert Adair
764 F.3d 347 (Fourth Circuit, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
CIARCIELLO v. BIOVENTUS INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/ciarciello-v-bioventus-inc-ncmd-2024.